Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west
Tóm tắt
Từ khóa
Tài liệu tham khảo
Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68, 394, 10.3322/caac.21492
Shi, 2010, Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus, Ann Surg Oncol, 17, 2073, 10.1245/s10434-010-0940-4
Minagawa, 2001, Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus, Ann Surg, 233, 379, 10.1097/00000658-200103000-00012
1998, A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators, Hepatology, 28, 751, 10.1002/hep.510280322
1990, Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment, Ann Surg, 211, 277
2018, European Association foEASL clinical practice guidelines: management of hepatocellular carcinoma, J Hepatol, 69, 182, 10.1016/j.jhep.2018.03.019
Bruix, 2016, Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma, Gastroenterology, 150, 835, 10.1053/j.gastro.2015.12.041
Marrero, 2018, Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases, Hepatology, 68, 723, 10.1002/hep.29913
Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857
Cheng, 2009, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, 10, 25, 10.1016/S1470-2045(08)70285-7
Omata, 2017, Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update, Hepatol Int, 11, 317, 10.1007/s12072-017-9799-9
Kudo, 2015, General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the outstanding achievements of the liver cancer study group of Japan, Dig Dis, 33, 765, 10.1159/000439101
2015, 2014 Korean liver cancer study group-national cancer center Korea practice guideline for the management of hepatocellular carcinoma, Korean J Radiol, 16, 465, 10.3348/kjr.2015.16.3.465
Cheng, 2016, Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus—Eastern Hepatobiliary Surgical Hospital consensus statement, Oncotarget, 7, 40816, 10.18632/oncotarget.8386
Kokudo, 2016, Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion, J Hepatol, 65, 938, 10.1016/j.jhep.2016.05.044
Yoon, 2018, Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial, JAMA Oncol, 4, 661, 10.1001/jamaoncol.2017.5847
Catalano, 2010, Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging, Radiology, 254, 154, 10.1148/radiol.09090304
Cheng, 2017, Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition, Oncotarget, 8, 8867, 10.18632/oncotarget.12817
Loffredo, 2017, Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis, Gastroenterology, 153, 480, 10.1053/j.gastro.2017.04.042
Ponziani, 2010, Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment, World J Gastroenterol, 16, 143, 10.3748/wjg.v16.i2.143
Zhang, 2018, An EHBH-PVTT scoring system as an aid to decision-making on hepatectomy for HCC patients with PVTT: a multicenter study, Hepatology
Peng, 2012, Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus, Cancer, 118, 4725, 10.1002/cncr.26561
Yu, 2015, Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein, World J Hepatol, 7, 1553, 10.4254/wjh.v7.i11.1553
2003
Ikai, 2003, Results of hepatic resection for hepatocellular carcinoma invading major portal and/or hepatic veins, Surg Oncol Clin N Am, 12, 65, 10.1016/S1055-3207(02)00082-0
Shuqun, 2007, Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein, Hepatogastroenterology, 74, 499
Wilhelm, 2008, Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling, Mol Cancer Ther, 7, 3129, 10.1158/1535-7163.MCT-08-0013
Bruix, 2012, Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial, J Hepatol, 57, 821, 10.1016/j.jhep.2012.06.014
Cheng, 2012, Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III sorafenib Asia-Pacific trial, Eur J Cancer, 48, 1452, 10.1016/j.ejca.2011.12.006
Park, 2019, Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial, J Hepatol, 70, 684, 10.1016/j.jhep.2018.11.029
Kudo, 2018, Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial, Lancet, 391, 1163, 10.1016/S0140-6736(18)30207-1
Bruix, 2017, Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 389, 56, 10.1016/S0140-6736(16)32453-9
Abou-Alfa, 2018, Cabozantinib in patients with advanced and progressing hepatocellular carcinoma, N Engl J Med, 379, 54, 10.1056/NEJMoa1717002
Zhu, 2015, Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial, Lancet Oncol, 16, 859, 10.1016/S1470-2045(15)00050-9
Qin, 2013, Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia, J Clin Oncol, 31, 3501, 10.1200/JCO.2012.44.5643
Qin, 2014, Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study, Oncologist, 19, 1169, 10.1634/theoncologist.2014-0190
El-Khoueiry, 2017, Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial, Lancet, 389, 2492, 10.1016/S0140-6736(17)31046-2
Zhu, 2018, Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial, Lancet Oncol, 19, 940, 10.1016/S1470-2045(18)30351-6
Kokudo, 2017, Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey, Hepatology, 66, 510, 10.1002/hep.29225
Wang, 2016, Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus: a large-scale, multicenter, propensity matching score analysis, Medicine (Baltimore), 95
Roayaie, 2013, Resection of hepatocellular carcinoma with macroscopic vascular invasion, Ann Surg Oncol, 20, 3754, 10.1245/s10434-013-3074-7
Pawlik, 2005, Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study, Surgery, 137, 403, 10.1016/j.surg.2004.12.012
Costentin, 2017, Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: a propensity score analysis, Liver Int, 37, 1869, 10.1111/liv.13491
Zhang, 2019, In-hospital mortality after surgical resection in hepatocellular carcinoma patients with portal vein tumor thrombus, J Cancer, 10, 72, 10.7150/jca.27102
Giannini, 2018, Patients with advanced hepatocellular carcinoma need a personalized management: a lesson from clinical practice, Hepatology, 67, 1784, 10.1002/hep.29668
Lee, 2017, Macrovascular invasion is not an absolute contraindication for living donor liver transplantation, Liver Transpl, 23, 19, 10.1002/lt.24610
Pommergaard, 2018, Vascular invasion and survival after liver transplantation for hepatocellular carcinoma: a study from the European liver transplant registry, HPB (Oxford), 20, 768, 10.1016/j.hpb.2018.03.002
Hamaoka, 2017, Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: a retrospective cohort study, Int J Surg, 44, 223, 10.1016/j.ijsu.2017.06.082
Liu, 2018, Postoperative adjuvant trans-arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus, Ann Surg Oncol, 25, 2098, 10.1245/s10434-018-6438-1
Emami, 1991, Tolerance of normal tissue to therapeutic irradiation, Int J Radiat Oncol Biol Phys, 21, 109, 10.1016/0360-3016(91)90171-Y
Liang, 2006, Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance, Int J Radiat Oncol Biol Phys, 65, 426, 10.1016/j.ijrobp.2005.12.031
Vogel, 2018, Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 29, 238, 10.1093/annonc/mdy308
Chow, 2016, National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma, Liver Cancer, 5, 97, 10.1159/000367759
Park, 2016, Consensus for radiotherapy in hepatocellular carcinoma from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): current practice and future clinical trials, Liver Cancer, 5, 162, 10.1159/000367766
Zhou, 2018, Guidelines for diagnosis and treatment of primary liver cancer in china (2017 edition), Liver Cancer, 7, 235, 10.1159/000488035
Yu, 2016, Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis, World J Gastroenterol, 22, 6851, 10.3748/wjg.v22.i30.6851
Nakazawa, 2014, Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis, BMC Gastroenterol, 14, 84, 10.1186/1471-230X-14-84
Huo, 2015, Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis, JAMA Oncol, 1, 756, 10.1001/jamaoncol.2015.2189
Yu, 2016, Clinical impact of combined transarterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: an external validation study, Radiother Oncol, 118, 408, 10.1016/j.radonc.2015.11.019
Im, 2017, Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area, Liver Int, 37, 90, 10.1111/liv.13191
Lin, 2019, Predictive factors of benefit from iodine-125 brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis, Brachytherapy, 18, 233, 10.1016/j.brachy.2018.10.002
Lu, 2017, Safety and efficacy of irradiation stent placement for malignant portal vein thrombus combined with transarterial chemoembolization for hepatocellular carcinoma: a single-center experience, J Vasc Interv Radiol, 28, 786, 10.1016/j.jvir.2017.02.014
Sun, 2018, Endovascular implantation of 125I seed combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma, Future Oncol, 14, 1165, 10.2217/fon-2017-0354
Zhu, 2018, Transarterial chemoembolization plus iodine-125 implantation for hepatocellular carcinoma: a systematic review and meta-analysis, HPB (Oxford), 20, 795, 10.1016/j.hpb.2018.03.015
Chuan-Xing, 2011, Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus: chemoembolization and stent combined with iodine-125 seed, Cancer Biol Ther, 12, 865, 10.4161/cbt.12.10.17676
Luo, 2016, Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus, Hepatol Int, 10, 185, 10.1007/s12072-015-9663-8
Huang, 2016, Survival benefit of chemoembolization plus Iodine125 seed implantation in unresectable hepatitis B-related hepatocellular carcinoma with PVTT: a retrospective matched cohort study, Eur Radiol, 26, 3428, 10.1007/s00330-015-4198-x
Kim, 2018, Chemoembolization related to good survival for selected patients with hepatocellular carcinoma invading segmental portal vein, Liver Int, 38, 1646, 10.1111/liv.13719
Choi, 2017, Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus, Eur Radiol, 27, 1448, 10.1007/s00330-016-4511-3
Park, 2015, Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study, Liver Int, 35, 2155, 10.1111/liv.12818
Yau, 2014, Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma, Gastroenterology, 146, 1691, 10.1053/j.gastro.2014.02.032
Luo, 2011, Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study, Ann Surg Oncol, 18, 413, 10.1245/s10434-010-1321-8
Niu, 2012, Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification, Med Oncol, 29, 2992, 10.1007/s12032-011-0145-0
Lv, 2018, Transarterial chemoembolization for hepatocellular carcinoma combined with portal vein tumor thrombosis, Cancer Manag Res, 10, 4719, 10.2147/CMAR.S166527
Chung, 2011, Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival, Radiology, 258, 627, 10.1148/radiol.10101058
Silva, 2017, Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis, HPB (Oxford), 19, 659, 10.1016/j.hpb.2017.04.016
Pawlik, 2011, Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma, J Clin Oncol, 29, 3960, 10.1200/JCO.2011.37.1021
Kudo, 2017, Transarterial chemoembolization in combination with a molecular targeted agent: lessons learned from negative trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2), Oncology, 93, 127, 10.1159/000481243
Kudo, 2018, Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial, Proc Am Soc Clin Oncol, 36, 206, 10.1200/JCO.2018.36.4_suppl.206
Zhu, 2014, Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study, Radiology, 272, 284, 10.1148/radiol.14131946
Benson, 2017, NCCN guidelines insights: hepatobiliary cancers, version 1.2017, J Natl Compr Canc Netw, 15, 563, 10.6004/jnccn.2017.0059
Kokudo, 2015, Evidence-based clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines), Hepatol Res, 10.1111/hepr.12464
Ueda, 2012, Toxicity and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (Review), Oncol Lett, 3, 259, 10.3892/ol.2011.469
Obi, 2015, Current status of hepatic arterial infusion chemotherapy, Liver Cancer, 4, 188, 10.1159/000367746
Choi, 2018, Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis, Cancer Chemother Pharmacol, 82, 469, 10.1007/s00280-018-3638-0
Lyu, 2018, Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma, J Hepatol, 69, 60, 10.1016/j.jhep.2018.02.008
Kudo, 2018, Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial, Lancet Gastroenterol Hepatol, 3, 424, 10.1016/S2468-1253(18)30078-5
He, 2019, Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial, JAMA Oncol
Kennedy, 2007, Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium, Int J Radiat Oncol Biol Phys, 68, 13, 10.1016/j.ijrobp.2006.11.060
Lau, 2013, Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90, Oncology, 84, 311, 10.1159/000348325
Inarrairaegui, 2010, Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis, J Vasc Interv Radiol, 21, 1205, 10.1016/j.jvir.2010.04.012
Salem, 2010, Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes, Gastroenterology, 138, 52, 10.1053/j.gastro.2009.09.006
Memon, 2013, Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression, J Hepatol, 58, 73, 10.1016/j.jhep.2012.09.003
Vilgrain, 2017, Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial, Lancet Oncol, 18, 1624, 10.1016/S1470-2045(17)30683-6
Chow, 2018, SIRveNIB: selective internal radiation therapy versus sorafenib in asia-pacific patients with hepatocellular carcinoma, J Clin Oncol, 36, 1913, 10.1200/JCO.2017.76.0892
Chan, 2016, Management of hepatocellular carcinoma with portal vein tumor thrombosis: review and update at 2016, World J Gastroenterol, 22, 7289, 10.3748/wjg.v22.i32.7289
de la Torre, 2016, A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib, Liver Int, 36, 1206, 10.1111/liv.13098
Edeline, 2016, Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis, Eur J Nucl Med Mol Imaging, 43, 635, 10.1007/s00259-015-3210-7
Ishikawa, 2014, Percutaneous transhepatic portal vein stent placement can improve prognosis for hepatocellular carcinoma patients with portal vein tumor thrombosis, Hepatogastroenterology, 61, 413
Yamakado, 1999, Clinical efficacy of portal vein stent placement in patients with hepatocellular carcinoma invading the main portal vein, J Hepatol, 30, 660, 10.1016/S0168-8278(99)80197-4
Wu, 2018, Stents combined with iodine-125 implantation to treat main portal vein tumor thrombus, World J Gastrointest Oncol, 10, 496, 10.4251/wjgo.v10.i12.496
Luo, 2011, Endovascular placement of iodine-125 seed strand and stent combined with chemoembolization for treatment of hepatocellular carcinoma with tumor thrombus in main portal vein, J Vasc Interv Radiol, 22, 479, 10.1016/j.jvir.2010.11.029
Zhang, 2018, Treatment of hepatocellular carcinoma with tumor thrombus with the use of iodine-125 seed strand implantation and transarterial chemoembolization: a propensity-score analysis, J Vasc Interv Radiol, 29, 1085, 10.1016/j.jvir.2018.02.013
Vibert, 2013, Portal stenting for hepatocellular carcinoma extending into the portal vein in cirrhotic patients, J Surg Oncol, 107, 696, 10.1002/jso.23306
Agarwal, 2017, Multidisciplinary management of hepatocellular carcinoma improves access to therapy and patient survival, J Clin Gastroenterol, 51, 845, 10.1097/MCG.0000000000000825
Chang, 2008, Implementation of a multidisciplinary treatment team for hepatocellular cancer at a veterans affairs medical center improves survival, HPB (Oxford), 10, 405, 10.1080/13651820802356572